Last updated: April 28, 2026
AU2015274838 (Australia): Scope, Claims, and Patent Landscape
AU2015274838 is an Australian patent publication tied to a specific drug invention and its associated claim set. However, this request cannot be completed to the required standard without the full published specification and claim text for AU2015274838, plus the relevant family members (priority, continuations, equivalents) and the prosecution/validation record. The patent’s “scope and claims” and the “landscape” depend on exact claim language, dependent-claim structure, claim interpretation factors, and family coverage across jurisdictions. With only the publication number provided and no text or bibliographic payload, a complete and accurate analysis cannot be produced.
What does AU2015274838 claim, and where is the claim scope anchored?
No claim text or specification content is available in the provided input. A scope analysis must quote and map:
- independent claim elements (active ingredient/formulation/route/dose/regimen/biomarker/salt/polymorph/device or combination, depending on the invention),
- dependent claim coverage (which additional features narrow or expand scope),
- claim construction hooks (definitions in the description, preferred embodiments, and claim dependencies),
- claim status (as filed, amended, or granted).
Without the actual claims for AU2015274838, any attempt to summarize scope would be speculative.
What is the patent family and how far does it extend beyond Australia?
A credible landscape requires:
- priority application(s) and filing dates,
- publication numbers and jurisdictions for the same invention,
- status of key members (granted, pending, expired, lapsed, opposition outcomes),
- whether AU2015274838 tracks to an innovator compound, a formulation, a method of treatment, or a new use.
None of these family facts are present in the input.
Which third-party patents compete in Australia around the same MoA/ingredient and time window?
A high-integrity landscape must identify:
- same-active or same-class patents in Australia (and their claim reach),
- overlapping method-of-treatment claims (dosing/regimen),
- overlapping formulation claims (salt/polymorph/particle size/excipients),
- “genus-species” coverage and whether later patents block earlier ones (or vice versa) through claim overlap.
This requires data mining of the Australian register and relevant foreign equivalents. No register search results are provided.
How does the competitive landscape map to expiry and exclusivity triggers in Australia?
A scope-and-landscape answer must tie patent coverage to:
- statutory patent term (and any extensions where applicable),
- any patent term extensions relevant to pharmaceuticals,
- effective date for novelty and priority,
- impact of invalidity risk points (lack of inventive step, insufficiency, or overbreadth).
Those inputs depend on the exact filing dates, priority dates, and claim features.
Key Takeaways
- AU2015274838 cannot be analyzed for claim scope or landscape with the required precision without the published claim set and family/prosecution data.
- A correct landscape requires exact claim language and structured extraction of independent and dependent claim elements, plus register status for Australia and key family members.
FAQs
-
Can you summarize AU2015274838’s claims without the claim text?
No. Claim scope in pharmaceuticals is element-driven, and exact wording plus dependencies are required for an accurate interpretation.
-
Do you need the entire patent specification to map drug claim scope?
Yes. The description can define terms, support claim interpretation, and indicate where the invention’s novelty sits.
-
What is required to build an Australian patent landscape for a single drug?
Bibliographic data for AU2015274838, full claim text, and a structured search for overlapping family members and third-party patents in Australia.
-
How do claim dependencies affect the practical scope of AU2015274838?
Dependencies constrain the minimum set of features needed to infringe and determine which manufacturing or clinical attributes fall within the protected invention.
-
What drives landscape conclusions on expiry and competitive risk?
Priority dates, filing dates, claim coverage breadth, and the grant status and enforceability of overlapping patents in Australia.
References
- No citable sources were provided in the input.
